Guidelines on the Diagnosis and Management of Multiple Myeloma
12. References
APBI (1999). Compendium of Data Sheets and Summaries of Product Characteristics. 1999-2000 edition. Datapharm Publications Ltd, London. pp 212 & 969.
Abrahamson GM, Bird JM, Newland AC et al. A randomised study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma Br J Haematol 1996; 94: 659-64.
Aitchison RG, Reilly IAG, Morgan AG, Russell NH. Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure. Br J Cancer 1990; 61: 765-6 [Medline abstract not available]
Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986; 105: 8-11
Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. J Am Med Assoc 1969; 208:1680-5 [Medline abstract not available]
Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Int Med 1990; 150: 1693-5.
Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86-9.
Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887-90.
Attal M, Harousseau JL, Stoppa AM et al. A prospective randomised trial of autologous transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-7.
Attal M, Harousseau JL, Facon T et al. Single versus double transplantation in myeloma: a prospective randomised trial of the Intergroupe Francophone du Myelome (IFM), Blood 2000; 96(11): 557a [Medline abstract not available].
Avvisati G, Petrucci MT, Mandelli F. The role of biotherapies (interleukin, interferons and erythropoietin) in multiple myeloma. Baillieres Clinical Haematology, 1995; 8: 815-29.
Badros A, Zangari M, Desikan R et al. Feasibility and efficacy of melphalan-based high dose therapy (Mel-HDT) with autologous peripheral blood stem cell support for patients with multiple myeloma aged > 70 years. Blood 1999; 94 (suppl 1): 578a [Medline abstract not available].
Badros A, Barlogie B, Morris C et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574-9.
Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-6.
Barlogie B, Desikan R, Eddlemon P et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98(2): 492-4.
Belch A. Shelley W. Bergsagel D. Wilson K et al. A randomised trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57: 94-9.
Belch AR, Bergsagel DE, Wilson K et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 1991; 9:1397-1402.
Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488-493.
Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998; 16: 593-602.
Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-200.
Bergsagel DE. The role of chemotherapy in the treatment of multiple myeloma. Baillieres Clinical Haematology 1995; 8: 783-794.
Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-8.
Bjorkstrand B, Svensson H, Goldschmidt H et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2001; 27: 511-515
Blade J, Esteve J. Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients? Med Oncol 2000; 17: 77-84.
Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisolone even in high-risk patients. J Clin Oncol 1991; 9: 444-448.
Brandes LJ, Israels LG. Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol 1987; 39: 362-8.
Brincker H, Westin J, Abildgaard N et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double blind placebo controlled trial. Danish-Swedish Co-operative Group. Br J Haematol 1998; 101: 280-6.
British Committee for Standards in Haematology Clinical Haematology Task Force. Guidelines on the provision of facilities for the care of adult patients with haematological malignancies (including leukaemia and lymphoma and severe bone marrow failure) Clin Lab Haematol 1995; 17: 3-10.
Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS. American Society of Clinical Oncology Practice Guidelines: The role of bisphosphonates in multiple myeloma. J Clinical Oncology 2002; 20: 3719-3736
Browman GP, Bergsagel D, Sicheri D et al. Randomised trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995; 13: 2354-60.
Bruce NJ, McCloskey EV, Kanis JA, Guest JF. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol 1999; 104: 358-64.
Bunn R & Ashley C (eds) 1999. The Renal Drug Handbook. Radcliffe Medical Press, Oxford pp 96 & 270.
Cameron JS. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 Suppl 2: 61-5.
Chapel HM, Lee M, Hargreaves, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase myeloma patients. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994; 343: 1059-63.
Clark RE, Brammer CG. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859-63.
Clark AD, Shetty A, Soutar R. Renal failure and multiple myeloma: pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Reviews 1999; 13: 79-90.
Cook G, Sharp RA, Tansey P, Franklin IM. A phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br J Haematol 1996; 93: 931-4.
Cook G. Marinaki P. Farrell E et al. Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy. Leukaemia. 1997; 11 (suppl. 5) S35-S40.
Cooper RB, Dear K, McIntyre OR et al. A randomised trial comparing melphalan / prednisolone with or without interferon alfa-2b in newly diagnosed patients with myeloma: a Cancer and Leukaemia Group B study. J Clin Oncol 1993;11: 155-60.
Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999: 17: 208-15.
Craddock C, Bardy P, Kreiter S et al. Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. Br J Haematol. 2000; 111: 797-800.
Cunningham D, Powles R, Malpas J et al. A randomised trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102: 495-502.
Dammacco F, Castoldi G, Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol 2001; 113: 172-9.
Delmas PD, Charhon S, Chapuy MC et al. Long term effects of dichloromethylene diphosphate (Cl2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res 1982; 4:163-8 [Medline abstract not available].
Demetri G, Kris M, Wade J, Degos L, Cella D. for the Proctrit Study Group. Quality-of-life benefit in chemotherapy patients treated with Epoietin Alfa is independent of disease response or tumour type: results from a prospective community oncology study. J Clin Oncol 1998; 16: 3412-25.
Demirer T, Buckner CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-41.
Desikan R, Barlogie B, Sawyer J et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008-10.
Desikan R, Veksler Y, Raza S, Stokes B, Sabir T, Jun Li Z, Jagannath S. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol 2002 119; 496-9
Dimopoulos MA, Moulopoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. Am J Med 1993; 94: 57-61.
Dimopoulos MA, Zervas K, Kouvatseas G et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001; 12: 991-5.
Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2001;(4):CD003188. Review
Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2002;(3):CD003188. Review.
Drayson M, Chapman CE, Dunn JA et al. MRC trial of a2b-interferon maintenance therapy in first plateau phase of multiple myeloma. Br J Haematol 1998; 101: 195-202.
Facon T, Avet-Loiseau H, Guillerm G et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-71.
Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomised clinical trial. Blood 1998; 92: 3131-6.
Fernberg JO, Johansson B, Lewensohn R, Mellstedt H. Oral dosage of melphalan and response to treatment in multiple myeloma. Eur J Cancer 1990; 26: 393-6.
Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000; 11: 1427-36.
Gahrton G. Allogeneic bone marrow transplantation in multiple myeloma. Br J Haematol 1996; 92: 251-4.
Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-16.
Ganeval D, Rabian C, Guerin V, Pertuiset N, Landais P, Jungers P. Treatment of multiple myeloma with renal involvement. Adv Nephrol Necker Hosp 1992; 21: 347-70 [Medline abstract not available].
Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with Epoietin Alfa on clinical outcomes of patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study group. J Clin Oncol 1997; 15: 1218-34.
Goldschmidt H, Bouko Y, Bourhis J-H et al. CD34 + selected PBPCT results in an increased infective risk without prologation of event-free survival in newly diagnosed myeloma: a randomised study from the EBMT Blood 2000; 96 (11): 558a [Medline abstract not available].
Gore ME. Selby PJ. Viner C et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2: 879-82.
Greipp PR. Advances in the diagnosis and management of myeloma. Semin Haematol 1992; 29: 24-45.
Gulbrandsen N, Wisloff F, Nord E, Lenhoff S, Hjorth M, Westin J. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol 2001; 66: 328-36.
Health Service Circular (1998). Better blood transfusion. HSC 1998/224 (PDF document).
Hjorth M, Hellquist L, Holmberg E, Magnusson B, Rodjer S, Westin J. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - a randomised study. Myeloma Group of Western Sweden. Eur J Haematol 1993; 50: 95-102.
Humphrey RL, Wright JR, Zachary JB, Sterioff S, DeFronzo RA. Renal transplantation in multiple myeloma. Ann Int Med 1975; 83: 651-3.
Johnson PW, Simnett SJ, Sweetenham JW, Morgan GJ, Stewart LA. Bone marrow and peripheral blood stem cell transplantation for malignancy. Health Technol Assess 1998; 2: 1-187 [Medline abstract not available].
Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Int Med 1990; 150: 863-9.
Jones SG, Dolan G, Lengyel, K, Myers B Severe increase in serum creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol 2002 119; 572-580 [Medline abstract not available]
Joshua D, Penny R, Matthews JP et al. Australian Leukaemia Study Group Myeloma II: a randomised trial of intensive combination chemotherapy with or without interferon in patients with myeloma. Br J Haematol 1997; 97: 38-45.
Juliusson G, Celsing F, Turesson I, Lenhoff S, Andriansson M, Malm C. Frequent good partial remissions with thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000; 109: 89-96.
Kelly K, Durie B, MacLennan ICM. Prognostic factors and staging system for myeloma: comparisons between the MRC studies in the United Kingdom and the Southwest Oncology Group studies in the United States. Hematol Oncol 1998; 6: 182-5.
Konigsberg R, Zojer N, Ackermann J et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000; 18: 804-12.
Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-25.
Kroger N, Kruger W, Renges H et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol. 2001; 112: 421-3.
Laakso M, Lahtinen R, Virkkunen , Elomaa I. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Br J Haematol 1994; 87: 735-9.
Lahtinen R, Laakso M, Palva I et al. Randomised placebo controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-1052.
Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population based study. Blood 2000; 95: 7-11.
Lokhorst HM, Sonneveld P, Verdonck LF. Intensive treatment for multiple myeloma: where do we stand? Br J Haematol 1999; 106: 18-27 [Medline abstract not available].
Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000; 18: 3031-7.
MacKinnon S. Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol 2000; 110(1): 12-7.
MacLennan IC, Cooper EH, Chapman CE, Kelly KA, Crockson RA. Renal failure in myelomatosis. Eur J Haematol 1989; 43 (suppl 1): 60-5.
MacLennan ICM, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992; 339: 200-205.
Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcaemia of malignancy: a pooled analysis of two randomised, controlled clinical trials. J Clin Oncol 2001; 19: 558-67.
Malpas JS. Clinical presentation and management. In: Myeloma biology and management. Eds Malpas JS, Bergsagel DE, Kyle R, Anderson K, 2nd edition, Oxford medical publications. 1998, 187-209.
Mandelli F, Avvisati G, Amadori S et al. Maintenance treatment with recombinant-alpha-2b interferon in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990; 332: 1430-4.
Mariette X. Zagdanski A-M. Guermazi A et al. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br J Haematol 1999; 104: 723-9.
McCloskey EV, MacLennan ICM, Drayson MT et al. A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998; 100: 317-25.
McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-400.
Medical Research Council's Working Party on Leukaemia in Adults. Myelomatosis: comparison of melphalan and cyclophosphamide therapy. Br Med J 1971; 1: 640-641 [Medline abstract not available].
Medical Research Council's Working Party on Leukaemia in Adults. Report on the second myelomatosis trial after five years of follow-up. Br J Cancer 1980(a); 42: 813-22.
Medical Research Council Working Party on leukaemia in adults Analysis and management of renal failure in 4th MRC Myelomatosis trial. Br Med J 1984; 288: 1411-1416.
Mehta J, Tricot G, Jagannath S et al. Salvage autologous or allogeneic transplantation refractory to or relapsing after a first line autograft. Bone Marrow Transplant 1998; 21: 887-98.
Mellstedt H, Bjorkholm M, Holm G. Intermittent melphalan and prednisolone therapy in plasma cell myeloma. Acta Med Scand 1977; 202: 5-9.
Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol. 2002 20:2353-59.
Morineau N, Tang XW, Moreau P, Milpied N, Mahe B, Bataille R, Harousseau JL. Lack of benefit of CD34+ cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study. Leukemia 2000; 14: 1815-20.
Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomised trials. J Clin Oncol 1998; 16: 3832-42.
Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001; 113: 1020-34.
Olojohungbe AB, Dunn JA, Drayson MT, MacLennan IM. Prednisolone added to the ABCM as treatment for multiple myeloma increases serological responses but not overall survival or the number of stable clinical responses. Br J Haematol 1996; 9 (suppl 1): 77 [Medline abstract not available].
Osterborg A, Ahre A, Bjorkholm M, et al. Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III - A randomised study from the MGCS. Eur J Haematol 1989; 43: 54-62.
Osterborg A, Ehrsson H, Eksborg S, Wallin I, Mellstedt H. Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. Eur J Clin Oncol 1989; 25: 899-903.
Osterborg A, Boogaerts MA, Cimino R et al. Recombinant human erythropoietin in transfusion-dependent anaemic patients with multiple myeloma and non-Hodgkin's lymphoma. Blood 1996; 87: 2675-82.
Palumbo A, Giaccone L, Bertola A et al. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica 2001; 86: 399-403.
Parameswaran R, Giles C, Boots M et al. CCNU (lomustine) idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma. Br J Haematol 2000; 109: 571-5
Peest D, Blade J, Harousseau JL. Cytokine therapy in multiple myeloma. Br J Haematol 1996; 94: 425-32.
Raje N. Powles R. Kulkarni S et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide(C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997; 97: 153-60.
Rajkumar SV, Fonseca R, Lacy MQ et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999; 23: 1267-72.
Riccardi A. Mora O. Tinelli C et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: A multicentre randomised study. Br J Cancer 2000; 82: 1254-60.
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-87
Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26: 1179-84.
Salmon SE, Haut A, Bonnet JD et al. Alternating combination chemotherapy and levamisole improve survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1983; 1: 453-61.
Sampson FC, Beard SM, Scott F, Vandenberghe E. Cost-effectiveness of high-dose therapy in first-line treatment of advanced multiple myeloma. Br Haematol 2001; 113: 1015-9.
Samson D, Gaminara E, Newland A et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989; 2: 882-5.
San Miguel JF, Blade C, Garcia-Sanz R. Treatment of multiple myeloma. Haematologica 1999; 84: 36-58.
Segeren CM, Sonneveld P, van der Holt B et al. Intensive versus double intensive therapy in previously untreated multiple myeloma: a prospective randomised phase III study in 450 patients. Absracts of the VIIIth International Myeloma Workshop, Banff, 2001 p 31 [Medline abstract not available].
Singer CR, Tobias JS, Giles F, Rudd GN, Blackman GM, Richards JD. Hemibody irradiation. An effective second-line therapy in drug-resistant multiple myeloma. Cancer 1989; 15: 2446-51.
Singhal S, Mehta J, Desikan R, Ayers D et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71.
Sirohi B, Powles R, Treleaven J et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000; 25: 533-9.
Stewart AK, Vescio R, Schiller G et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771-9.
Tosi P, Cavo M, Zamagni , Ronconi S, Benni M, Tura S. Multicentric randomised clinical trial comparing single vs double autologous peripheral blood stem cell transplantation for patients with newly diagnosed multiple myeloma: results of an interim analysis. Blood 1999; 94 (suppl 1): 715a [Medline abstract not available].
Tricot G, Jagannath S, Vesole D et al. (a) Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-96.
Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. (b) Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16: 7-11.
Vesole DH, Crowley JJ, Catchatourian R et al. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. J Clin Oncol 1999; 17: 2173 - 9.
Walker F, Bear RA. Renal transplantation in light chain myeloma. Am J Nephrol 1983; 3: 34-7 [Medline abstract not available].
Weber DM, Dimopoulos MA, Moulopoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. Br J Haematol 1997; 97: 810-4.
Westin J, Rodjer S, Turesson I et al. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomised study. Br J Haematol 1995; 89: 561-8.
Winearls CG. Acute myeloma kidney. Kid Int 1995; 48: 1347-61 [Medline abstract not available].
Wisloff F, Gulbrandsen N, Nord E. Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality of life considerations. Pharmacoeconomics 1999; 16: 329-41.
Wisloff F, Hjorth M, Kaasa S, Westin J. Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomised trial comparing melphalan-prednisolone to melphalan-prednisolone + alpha-interferon. The Nordic Myeloma Study Group Br J Haematol 1996; 94: 324-32.
Zojer N, Konigsberg R, Ackerman J et al. Deletion of 13q14 remains an independent prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridisation Blood 2000; 95: 1925-30.
Zucchelli P, Pasquali S, Cagnoli
L, Ferrari G. Controlled plasma exchange trial in acute renal failure
due to multiple myeloma. Kidney
Int 1988; 33: 1175-80.